BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25887287)

  • 21. Preoperative chemotherapy with S-1 and cisplatin for highly advanced gastric cancer.
    Nashimoto A; Yabusaki H; Nakagawa S; Takii Y; Tsuchiya Y; Otsuo T
    Anticancer Res; 2009 Nov; 29(11):4689-96. PubMed ID: 20032421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Systemic Inflammatory Response Biomarkers in Patients Receiving Chemotherapy for Unresectable and Recurrent Advanced Gastric Cancer.
    Namikawa T; Munekage E; Munekage M; Maeda H; Yatabe T; Kitagawa H; Kobayashi M; Hanazaki K
    Oncology; 2016; 90(6):321-6. PubMed ID: 27225990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Relevance of Postoperative Neutrophil-Lymphocyte Ratio (NLR) to Recurrence After Adjuvant Chemotherapy of S-1 for Gastric Cancer.
    Tanaka H; Tamura T; Toyokawa T; Muguruma K; Miki Y; Kubo N; Sakurai K; Hirakawa K; Ohira M
    Anticancer Res; 2018 Jun; 38(6):3745-3751. PubMed ID: 29848737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
    Huang D; Ba Y; Xiong J; Xu N; Yan Z; Zhuang Z; Yu Z; Wan H; Zhang Y; Deng T; Zheng R; Guo Z; Hu C; Wang M; Yu Z; Yao Y; Meng J
    Eur J Cancer; 2013 Sep; 49(14):2995-3002. PubMed ID: 23810466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of S-1 plus Cisplatin Neoadjuvant Chemotherapy on Scirrhous Gastric Cancer.
    Kunisaki C; Makino H; Kimura J; Takagawa R; Kanazawa A; Ota M; Kosaka T; Ono HA; Akiyama H; Endo I
    Oncology; 2015; 88(5):281-8. PubMed ID: 25591954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
    Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
    Ajani JA; Rodriguez W; Bodoky G; Moiseyenko V; Lichinitser M; Gorbunova V; Vynnychenko I; Garin A; Lang I; Falcon S
    J Clin Oncol; 2010 Mar; 28(9):1547-53. PubMed ID: 20159816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein-bound polysaccharide K partially prevents apoptosis of circulating T cells induced by anti-cancer drug S-1 in patients with gastric cancer.
    Kono K; Kawaguchi Y; Mizukami Y; Mimura K; Sugai H; Akaike H; Fujii H
    Oncology; 2008; 74(3-4):143-9. PubMed ID: 18708731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
    N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy.
    Luo G; Guo M; Liu Z; Xiao Z; Jin K; Long J; Liu L; Liu C; Xu J; Ni Q; Yu X
    Ann Surg Oncol; 2015 Feb; 22(2):670-6. PubMed ID: 25155401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK).
    Yoshinaga K; Saeki H; Oki E; Morita M; Ikeda T; Sugimachi K; Yamashita Y; Ikegami T; Uchiyama H; Yoshizumi T; Soejima Y; Kawanaka H; Mimori K; Watanabe M; Maehara Y
    Fukuoka Igaku Zasshi; 2013 Dec; 104(12):549-58. PubMed ID: 24693683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
    Huang DZ; Xiong JP; Xu N; Yan Z; Zhuang ZX; Yu Z; Wan HP; Zhang Y; Deng T; Zheng RS; Guo ZQ; Hu CH; Wang ML; Yu ZH; Yao Y; Meng JC; Ba Y
    Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):865-8. PubMed ID: 23291139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of preoperative neutrophils to lymphocytes ratio in patients resected for gastric cancer.
    Graziosi L; Marino E; De Angelis V; Rebonato A; Cavazzoni E; Donini A
    Am J Surg; 2015 Feb; 209(2):333-7. PubMed ID: 25190544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1.
    Hsu JT; Hsu CS; Le PH; Chen TC; Chou WC; Lin CY; Yeh TS
    J Surg Res; 2017 May; 211():30-38. PubMed ID: 28501128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Novel Scoring System Based on Fibrinogen and the Neutrophil-Lymphocyte Ratio as a Predictor of Chemotherapy Response and Prognosis in Patients with Advanced Gastric Cancer.
    Arigami T; Uenosono Y; Ishigami S; Okubo K; Kijima T; Yanagita S; Okumura H; Uchikado Y; Kijima Y; Nakajo A; Kurahara H; Kita Y; Mori S; Maemura K; Natsugoe S
    Oncology; 2016; 90(4):186-92. PubMed ID: 26981856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients.
    Miyamoto R; Inagawa S; Sano N; Tadano S; Adachi S; Yamamoto M
    Eur J Surg Oncol; 2018 May; 44(5):607-612. PubMed ID: 29478743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count.
    Toge T; Yamaguchi Y
    Oncol Rep; 2000; 7(5):1157-61. PubMed ID: 10948356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.
    Blum M; Suzuki A; Ajani JA
    Future Oncol; 2011 Jun; 7(6):715-26. PubMed ID: 21675835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.